SPTBN4 and axonal neuropathy: With the accumulation of data on βIV-spectrinopathies, it seems rational that SPTBN4 genetic testing should also be considered in patients with early-onset hypotonia, motor developmental delay, and intellectual disability, especially in the presence of axonal neuropathy, deafness, or pathological discharge patterns on the EEG.